Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Goodman

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Clinical Therapeutics|November 14, 2015
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled TrialAngela Applebee, Andrew D Goodman, Angeli S Mayadev, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta, Melissa K Samuelsson, Anatole K Kleiner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairmentJeffrey A Cohen, Michelle H Cameron, Myla D Goldman, et al.
Eclinicalmedicine|May 1, 2023
High-dose vitamin D<sub>3</sub> supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trialSandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Unemployment in multiple sclerosis: the contribution of personality and diseaseLauren B Strober, Christopher Christodoulou, Ralph H B Benedict, et al.
CNS Drugs|December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release FampridineJeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 26, 2021
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosisRobert J Fox, Paola Raska, Christian Barro, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Clinical Therapeutics|November 14, 2015
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled TrialAngela Applebee, Andrew D Goodman, Angeli S Mayadev, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta, Melissa K Samuelsson, Anatole K Kleiner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairmentJeffrey A Cohen, Michelle H Cameron, Myla D Goldman, et al.
Eclinicalmedicine|May 1, 2023
High-dose vitamin D<sub>3</sub> supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trialSandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Unemployment in multiple sclerosis: the contribution of personality and diseaseLauren B Strober, Christopher Christodoulou, Ralph H B Benedict, et al.
CNS Drugs|December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release FampridineJeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 26, 2021
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosisRobert J Fox, Paola Raska, Christian Barro, et al.
Pageof 5